Market News & Trends
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 & its Library of 500+ Proprietary Compounds
GRI Bio, Inc. recently announced the European Patent Office (EPO) has issued a decision to grant notice for patent application number 19,166,502 titled, Oxygenated Amino-…
Apollomics Announces Top-line Results for Phase 3 Trial of Uproleselan in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Inc. recently announced the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia.…
Lonza Capsules & Health Ingredients Expands Capsule Manufacturing Capacity in India & China
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced capacity expansions at its sites in Rewari (IN) and Suzhou (CN).…
Shuttle Pharma Enters Sponsored Research Agreement With the University of California, San Francisco to Advance PSMA Development Program
Shuttle Pharmaceuticals Holdings, Inc. recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics,…
Assembly Biosciences Announces $30.1 Million Investment & Accelerated Funding From Gilead
Assembly Biosciences, Inc. recently announced an equity investment of $20.1 million by Gilead Sciences, Inc. to purchase additional Assembly Bio common stock and an amendment…
IMUNON Announces Positive CMC Meeting With FDA for Advanced Ovarian Cancer Treatment
IMUNON, Inc. recently announced the positive outcome of a Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the US FDA regarding production of IMNN-001…
Gelteq Appoints New Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
Gelteq Limited recently announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer (CSO). Gelteq co-founder and CEO Nathan Givoni said “We believe…
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative
ABVC BioPharma, Inc. recently announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC believes its ABV-1504, which has…
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, underscores its…
Vandria Announces First Subjects Dosed in First-in-Human Phase 1 Trial of VNA-318 Brain-Penetrant Mitophagy Inducer
Vandria SA recently announced the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout…
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma
Coherus BioSciences, Inc. recently announced an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and…
Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
Polyrizon Ltd. announced it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice (GMP) manufacturer. This collaboration will…
Silo Pharma Initiates Pharmacokinetic & Tolerability Study for SP-26 Targeting Chronic Pain & Fibromyalgia
Silo Pharma, Inc. recently announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study…
SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the company’s second-generation…
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Channel Therapeutics Corporation recently announced it achieved its endpoints in two pre-clinical in vivo models of its nerve block formulations for acute pain, showing material…
Safi Biotherapeutics Granted Rare Pediatric Disease Designation & Orphan Drug Designation
Safi Biotherapeutics recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to their manufactured red blood cells…
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation From FDA for its Investigational Gene Therapy for Patients With Retinal Dystrophy Due to PDE6b Gene Mutations
eyeDNA Therapeutics recently announced that it has been granted a Rare Pediatric Disease Designation (RPDD) by the US FDA for HORA-PDE6b, its novel gene therapy…
Silexion Therapeutics Collaborates With Evonik on Advanced siRNA Formulation Development
Silexion Therapeutics Corp. recently announced its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed…
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE Clinical Trial
Eton Pharmaceuticals, Inc. announced the full readout and compelling results from the clinical trial evaluating PKU GOLIKE as a protein substitute for the treatment of…
GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar
GlycoNex, Inc. recently announced the first patient has been dosed in the Phase 3 clinical trial of its denosumab biosimilar, SPD8. This marks the initiation…
